Loading...
Novo Nordisk A/S
NOVC.DE•XETRA
HealthcareMedical - Pharmaceuticals
€91.40
€-1.85(-1.98%)
Novo Nordisk A/S (NOVC.DE) Financial Performance & Statements
Review Novo Nordisk A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
25.03%
↑ 25.03%
Operating Income Growth
25.12%
↑ 25.12%
Net Income Growth
20.68%
↑ 20.68%
Operating Cash Flow Growth
11.07%
↑ 11.07%
Operating Margin
43.84%
↑ 43.84%
Gross Margin
84.66%
↑ 84.66%
Net Profit Margin
35.006%
↑ 35.006%
ROE
86.40%
↑ 86.40%
ROIC
62.74%
↑ 62.74%
Novo Nordisk A/S (NOVC.DE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Novo Nordisk A/S stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $85.68B | $71.31B | $68.06B | $65.35B |
| Cost of Revenue | $13.02B | $11.31B | $10.27B | $9.92B |
| Gross Profit | $72.66B | $60.003B | $57.79B | $55.43B |
| Gross Profit Ratio | $0.85 | $0.84 | $0.85 | $0.85 |
| R&D Expenses | $13.80B | $9.49B | $16.17B | $8.61B |
| SG&A Expenses | $20.28B | $16.59B | $16.09B | $14.41B |
| Operating Expenses | $35.92B | $26.08B | $32.26B | $23.02B |
| Total Costs & Expenses | $48.95B | $37.39B | $42.53B | $32.94B |
| Interest Income | $0.00 | $1.38B | $960.00M | $2.15B |
| Interest Expense | $0.00 | $821.00M | $1.56B | $2.07B |
| Depreciation & Amortization | $5.20B | $4.50B | $8.85B | $2.91B |
| EBITDA | $40.14B | $38.88B | $35.74B | $35.33B |
| EBITDA Ratio | $0.47 | $0.55 | $0.51 | $0.54 |
| Operating Income | $36.74B | $33.92B | $25.53B | $32.41B |
| Operating Income Ratio | $0.43 | $0.48 | $0.38 | $0.50 |
| Other Income/Expenses (Net) | -$1.18B | $461.00M | -$602.00M | -$496.00M |
| Income Before Tax | $35.56B | $34.38B | $25.33B | $31.92B |
| Income Before Tax Ratio | $0.41 | $0.48 | $0.37 | $0.49 |
| Income Tax Expense | $7.33B | $7.08B | $5.28B | $6.51B |
| Net Income | $28.23B | $27.30B | $20.05B | $25.41B |
| Net Income Ratio | $0.33 | $0.38 | $0.29 | $0.39 |
| EPS | $6.34 | $6.13 | $4.50 | $5.70 |
| Diluted EPS | $6.33 | $6.12 | $4.49 | $5.68 |
| Weighted Avg Shares Outstanding | $4.45B | $4.45B | $4.46B | $4.46B |
| Weighted Avg Shares Outstanding (Diluted) | $4.46B | $4.46B | $4.47B | $4.47B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan